$30.86
4.65% day before yesterday
Nasdaq, Jan 02, 10:11 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US60770K1079
Symbol
MRNA

Moderna Stock price

$30.86
+6.80 28.26% 1M
+0.58 1.92% 6M
+1.37 4.65% YTD
-11.14 26.52% 1Y
-148.76 82.82% 3Y
-80.87 72.38% 5Y
+12.26 65.91% 10Y
+12.26 65.91% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+1.37 4.65%
ISIN
US60770K1079
Symbol
MRNA
Industry

New AI Insights on Moderna Insights AI Insights on Moderna

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$12.1b
Enterprise Value
$7.6b
Net debt
positive
Cash
$4.5b
Shares outstanding
391.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.4 | 6.2
EV/Sales
3.4 | 3.9
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
77.1%
Return on Equity
-32.7%
ROCE
-29.9%
ROIC
-43.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.2b | $1.9b
EBITDA
$-2.9b | $-3.2b
EBIT
$-3.1b | $-3.5b
Net Income
$-3.1b | $-3.2b
Free Cash Flow
$-2.7b
Growth (TTM | estimate)
Revenue
-56.1% | -40.1%
EBITDA
-61.6% | 2.1%
EBIT
-46.3% | -0.9%
Net Income
-40.1% | 9.8%
Free Cash Flow
32.7%
Margin (TTM | estimate)
Gross
63.5%
EBITDA
-130.6% | -164.7%
EBIT
-139.9%
Net
-139.6% | -165.8%
Free Cash Flow
-119.3%
More
EPS
$-8.0
FCF per Share
$-6.8
Short interest
21.7%
Employees
6k
Rev per Employee
$560.0k
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Moderna forecast:

4x Buy
14%
18x Hold
62%
7x Sell
24%

Analyst Opinions

29 Analysts have issued a Moderna forecast:

Buy
14%
Hold
62%
Sell
24%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,232 2,232
56% 56%
100%
- Direct Costs 815 815
26% 26%
37%
1,417 1,417
64% 64%
63%
- Selling and Administrative Expenses 1,061 1,061
18% 18%
48%
- Research and Development Expense 3,479 3,479
28% 28%
156%
-2,915 -2,915
62% 62%
-131%
- Depreciation and Amortization 208 208
37% 37%
9%
EBIT (Operating Income) EBIT -3,123 -3,123
46% 46%
-140%
Net Profit -3,116 -3,116
40% 40%
-140%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Positive
The Motley Fool
16 days ago
Moderna's earnings and stock price climbed during early pandemic days -- that's as demand for the company's coronavirus vaccine soared. Since, the company has faced various challenges that have weighed on investors' appetite for the stock.
Positive
Reuters
16 days ago
Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.
Neutral
Accesswire
16 days ago
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at afforda...
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today